Enhanced protection from fibrosis and inflammation in the combined absence of IL‐13 and IFN‐γ
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Persistent or dysregulated IL‐13 responses are key drivers of fibrosis in multiple organ systems, and this identifies this cytokine as an important therapeutic target. Nevertheless, the mechanisms by which IL‐13 blockade leads to the amelioration of fibrosis remain unclear. Because IFN‐γ exhibits potent anti‐fibrotic activity, and IL‐4Rα signalling antagonizes IFN‐γ effector function, compensatory increases in IFN‐γ activity following IL‐13/IL‐4Rα blockade might contribute to the reduction in fibrosis. To investigate the role of IFN‐γ, we developed novel IL‐13−/−/IFN‐γ−/− double cytokine‐deficient mice and examined disease progression in models of type 2‐driven fibrosis. As predicted, we showed that fibrosis in the lung and liver are both highly dependent on IL‐13. We also observed increased IFN‐γ production and inflammatory activity in the tissues of IL‐13‐deficient mice. Surprisingly, however, an even greater reduction in fibrosis was observed in IL‐13/IFN‐γ double deficient mice, most notably in the livers of mice chronically infected with Schistosoma mansoni. The increased protection was associated with marked decreases in Tgfb1, Mmp12, and Timp1 mRNA expression in the tissues; reduced inflammation; and decreased expression of important pro‐inflammatory mediators such as TNF‐α. Experiments conducted with neutralizing monoclonal antibodies to IL‐13 and IFN‐γ validated the findings with the genetically deficient mice. Together, these studies demonstrate that the reduction in fibrosis observed when IL‐13 signalling is suppressed is not dependent on increased IFN‐γ activity. Instead, by reducing compensatory increases in type 1‐associated inflammation, therapeutic strategies that block IFN‐γ and IL‐13 activity simultaneously can confer greater protection from progressive fibrosis than IL‐13 blockade alone. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 2×
“In addition to their well-defined roles in allergic disease and immunity to gastrointestinal parasites [8,9], chronic IL-13 responses are also directly involved in the development of pathological fibrosis [10,11].”
BackgroundSelf-citationFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Self-citationAcquisition of lymphokine-producing phenotype by CD4+ T cells
Seder, R. A., & Paul, W. E. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.003223 · Cited by 1,557
Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors
Trengove, N. J., Stacey, M. C., Macauley, S., Bennett, N., Gibson, J., Burslem, F., Murphy, G., & Schultz, G. (1999) · Wound Repair and Regeneration · doi:10.1046/j.1524-475x.1999.00442.x · Cited by 908
Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription
Zhang, Y., Feng, X.-H., & Derynck, R. (1998) · Nature · doi:10.1038/29814 · Cited by 809 · cited 1×
“Indeed, the pro-fibrotic cytokine TGF-β also serves as a potent anti-inflammatory mediator [32,57], with deficiencies in Tgfb1 or TGF-β1 signalling linked with the development of numerous autoimmune and inflammatory diseases [58,59].”
BackgroundA placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652 · cited 1×
“cytokine responses [39–42], with IFN-γ suppressing myofibroblast function and IL-4 and IL-13 augmenting their activity [16,43].”
BackgroundChiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603 · cited 2×
“cytokine responses [39–42], with IFN-γ suppressing myofibroblast function and IL-4 and IL-13 augmenting their activity [16,43].”
BackgroundSelf-citationT H 2 and T H 17 inflammatory pathways are reciprocally regulated in asthma
Choy, D. F., Hart, K. M., Borthwick, L. A., Shikotra, A., Nagarkar, D. R., Siddiqui, S., Jia, G., Ohri, C. M., Doran, E., Vannella, K. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3142 · Cited by 450 · cited 2×
“Type 2 cytokine responses, defined by the cytokines interleukin-4 (IL-4), IL-5, IL-9, and IL-13, and type 1 responses characterized by IL-12 and IFN-γ [1] play distinct roles in immunity, inflammation, and fibrosis, and both responses undergo significant cross-regulation or suppression by the opposing pathway [2,3].”
BackgroundResultSelf-citationIL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370 · cited 2×
“Interestingly, although fibrosis was significantly decreased in the livers of IL-13−/− mice, Tgfb1 expression was maximally elevated in this group, thus supporting previous studies that concluded that TGF-β1 plays little to no role in the pathogenesis of schistosomiasis in WT mice [26] (Figure 4).”
BackgroundResultSelf-citationShi, Z., Wakil, A. E., & Rockey, D. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10663 · Cited by 310
Modulation of murine macrophage function by IL-13
Doherty, T. M., Kastelein, R., Menon, S., Andrade, S., & Coffman, R. L. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.12.7151 · Cited by 249
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts
Oriente, A., Fedarko, N. S., Pacocha, S. E., Huang, S.-K., Lichtenstein, L. M., & Essayan, D. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35380-7 · Cited by 230
Macrophages are critical to the maintenance of IL-13-dependent lung inflammation and fibrosis
Borthwick, L. A., Barron, L., Hart, K. M., Vannella, K. M., Thompson, R. W., Oland, S., Cheever, A., Sciurba, J., Ramalingam, T. R., Fisher, A. J., et al. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.34 · Cited by 138
Self-citation
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Self-citationInflammation and metabolism in tissue repair and regeneration
Eming, S. A., Wynn, T. A., & Martin, P. (2017) · Science · doi:10.1126/science.aam7928 · Cited by 1,369
Self-citationType 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Self-citationSciurba, J. C., Gieseck, R. L., Jiwrajka, N., White, S. D., Karmele, E. P., Redes, J., Vannella, K. M., Henderson, N. C., Wynn, T. A., & Hart, K. M. (2019) · The Journal of Pathology · doi:10.1002/path.5215 · Cited by 22
Self-citation
Metadata
- Authors
- Ramalingam, T. R., Gieseck, R. L., Acciani, T. H., M Hart, K., Cheever, A. W., Mentink‐Kane, M. M., Vannella, K. M., & Wynn, T. A.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2016-06-10
- Volume
- 239
- Issue
- 3
- Pages
- 344-354
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2344330301
- Cited by
- 55
- References
- 13
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.